Evidence map›Paper›PMID 40220033›Full record

ArticleJournal of hematopathology2025

Nucleolated cells in extranodal marginal zone lymphoma: a case report and discussion of circulating lymphoma cells with prominent nucleoli.

Beatriz Rocha-Rodrigues, Roberto N Miranda, L Jeffrey Medeiros

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Beatriz Rocha-RodriguesUniversidade Anhembi Morumbi, São Paulo, Brazil.
Roberto N MirandaThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
L Jeffrey MedeirosThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. ljmedeiros@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various types of lymphoma/leukemia can present with leukemic involvement by neoplastic cells with prominent nucleoli. Patients with chronic lymphocytic leukemia (CLL) most commonly can present in this fashion but other, less common types include mantle cell lymphoma, splenic marginal zone lymphoma, splenic diffuse red pulp small B-cell lymphoma, and splenic B-cell lymphoma/leukemia with prominent nucleoli (SBLPN). The latter is a newly proposed category in the fifth edition of the World Health Organization classification of hematolymphoid neoplasms. This category includes most cases that were previously designated hairy cell leukemia-variant and rare cases of CD5-negative B-prolymphocytic leukemia. A case of extranodal marginal zone lymphoma (EMZL) is reported to highlight the presence of nucleolated lymphocytes in the peripheral blood and bone marrow and their impact on the differential diagnosis, particularly with SBLPN. An 80-year-old woman with a reported history of "CLL", diagnosed and treated with clinical remission, developed gastric EMZL which relapsed twice after chemotherapy. At time of last relapse, a peripheral blood smear and bone marrow aspiration and biopsy specimens were evaluated to assess the presence and extent of blood and bone marrow involvement. The pathologic findings and differential diagnosis are discussed. A complete blood count showed a leukocyte count of 7.9 × 10

Indexed as

Cell NucleolusLymphoma, B-Cell, Marginal ZoneNeoplastic Cells, CirculatingAged, 80 and overDiagnosis, DifferentialFemaleHumansExtranodalHairy cell leukemia variantMarginal zone lymphoma (MZL)SplenicSplenic B-cell lymphoma/leukemia with prominent nucleoli (SBLPN)Splenic lymphomas

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.